» Articles » PMID: 38456950

3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients  with Multiple Myeloma Using Whole-body MRI

Abstract

Although magnetic resonance imaging (MRI) data of patients with multiple myeloma (MM) are used to predict prognosis, few reports have applied artificial intelligence (AI) techniques for this purpose. We aimed to analyze whole-body diffusion-weighted MRI data using three-dimensional (3D) convolutional neural networks (CNNs) and Gradient-weighted Class Activation Mapping (Grad-CAM), an explainable AI, to predict prognosis and explore the factors involved in prediction. We retrospectively analyzed the MRI data of a total of 142 patients with MM obtained from two medical centers. We defined the occurrence of progressive disease after MRI evaluation within 12 months as a poor prognosis and constructed a 3D CNN-based deep learning model to predict prognosis. Images from 111 cases were used as the training and internal validation data; images from 31 cases were used as the external validation data. Internal validation of the AI model with stratified 5-fold cross-validation resulted in a significant difference in progression-free survival (PFS) between good and poor prognostic cases (2-year PFS, 91.2% versus [vs.] 61.1%, P = 0.0002). The AI model clearly stratified good and poor prognostic cases in the external validation cohort (2-year PFS, 92.9% vs. 55.6%, P = 0.004), with an area under the receiver operating characteristic curve of 0.804. According to Grad-CAM, the MRI signals of the spleen and bones of the vertebrae and pelvis contributed to prognosis prediction. This study is the first to show that image analysis of whole-body MRI using a 3D CNN without any other clinical data is effective in predicting the prognosis of patients with MM.

Citing Articles

Advancements in Multiple Myeloma Research: High-Throughput Sequencing Technologies, Omics, and the Role of Artificial Intelligence.

Gutierrez-Gonzalez A, Del Hierro I, Cariaga-Martinez A Biology (Basel). 2024; 13(11).

PMID: 39596878 PMC: 11592186. DOI: 10.3390/biology13110923.


The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.

More S, Corvatta L, Manieri V, Morsia E, Offidani M Cancers (Basel). 2024; 16(12).

PMID: 38927968 PMC: 11202048. DOI: 10.3390/cancers16122263.

References
1.
Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

2.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

3.
DAgostino M, Cairns D, Lahuerta J, Wester R, Bertsch U, Waage A . Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022; 40(29):3406-3418. DOI: 10.1200/JCO.21.02614. View

4.
Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L . Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009.... J Clin Oncol. 2017; 35(25):2911-2918. PMC: 5578392. DOI: 10.1200/JCO.2017.72.2975. View

5.
Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M . Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. Cancer Med. 2021; 10(17):5859-5865. PMC: 8419770. DOI: 10.1002/cam4.4136. View